Latest Regulatory News

MyEco Group Ltd reported an 8.6% revenue increase to $15.7 million in FY25, driven by strong growth in its MyEco® branded products and improved margins. The company cut its net loss by nearly half, supported by operational restructuring and expanding market presence.

Australian Finance Group Ltd (AFG) reported a 21% rise in statutory net profit after tax to $35 million for FY25, driven by record broker numbers and loan book growth. The company declared a fully franked final dividend of 5.3 cents per share, underscoring strong shareholder returns.

Cash Converters International Limited reported robust FY25 results, driven by strategic franchise acquisitions and a shift to longer-term, lower-cost lending products. The company is poised for further growth with new loan launches and luxury retail expansion.

Cash Converters International Limited reported a robust 41% increase in net profit for FY2025, driven by strategic franchise acquisitions and a shift in loan product mix. The company declared a fully franked final dividend and maintains a strong balance sheet as it navigates evolving regulatory and market conditions.

Horizon Minerals is progressing its Pre-Feasibility Study to convert the Black Swan plant to gold production, aiming for a 1.5Mtpa throughput and a Financial Investment Decision by early 2026.

Terragen Holdings reported a $3.72 million loss for FY25, impacted by drought and lower revenues, while launching dry probiotic products targeting feedlots and completing a $4.76 million equity raise.

Meridian Energy posted a significant net loss for FY25 due to severe droughts and gas shortages but pushed ahead with renewable investments and maintained shareholder dividends.

Yancoal Australia has appointed Sharif Burra as its permanent CEO, signaling leadership continuity amid a challenging coal market. Burra’s deep internal experience positions him to build on recent operational gains and shareholder value.

Cleo Diagnostics reported a $4 million loss for FY2025 while making significant strides toward FDA approval of its novel ovarian cancer blood test. The company is progressing clinical trials and scaling manufacturing in preparation for market entry.

Race Oncology Limited reported a significantly reduced loss for FY2025, driven by key clinical trial progress and strategic leadership changes. The company advances its RC220 program with promising Phase 1 dosing milestones and strengthens its governance to support future growth.

Marvel Gold Limited has restructured its Mali asset sale with Anchises Capital, securing a $250,000 equity injection while revising terms for its Tabakorole Gold Project sale.

WCM Global Growth Limited reported a robust FY2025 with a 31% portfolio return and raised its fully franked final dividend, alongside an upgraded progressive dividend policy and a shareholder-friendly DRP discount.